Pharmaceutical company Eli Lilly on Wednesday said that its combination of two antibody drugs to fight the coronavirus cuts the risk of hospitalization and death by 87 percent.
The finding is based on a study of 769 high-risk COVID-19 patients aged 12 and older with mild to moderate COVID-19.
The company said that no patients who were treated with the combination of bamlanivimab and etesevimab died. Four people who were in the placebo group died from the coronavirus.
“I expect this data to continue to drive more utilization” of the antibodies,” said Daniel Skovronsky, chief scientific officer at Eli Lilly.
“We have few other diseases where we have drugs that can offer this magnitude of benefit.”
This was the second large, late-stage study to show that the antibody therapy is effective at treating mild to moderate cases of COVID-19.
The previous study, which was revealed in January, used a higher dose of the drugs and reduced risk of hospitalization by 70 percent.
US regulators first authorized the combination therapy in February for use in COVID-19 patients 12 and up who are at high risk of coming down with a serious case of the virus.
That month, the US agreed to purchase a minimum of 100,000 doses of the combination treatment.
With Post wires